-
公开(公告)号:US10421744B2
公开(公告)日:2019-09-24
申请号:US16123072
申请日:2018-09-06
申请人: PFIZER INC.
发明人: Michael Aaron Brodney , Jennifer Elizabeth Davoren , Amy Beth Dounay , Ivan Viktorovich Efremov , David Lawrence Firman Gray , Michael Eric Green , Jaclyn Louise Henderson , Chewah Lee , Scot Richard Mente , Steven Victor O'Neil , Bruce Nelsen Rogers , Lei Zhang
IPC分类号: C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , A61K31/444 , A61K31/606 , A61K31/513 , A61K31/501 , A61P25/18 , A61P25/28 , A61K31/506
摘要: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.
-
公开(公告)号:US09822097B2
公开(公告)日:2017-11-21
申请号:US15349075
申请日:2016-11-11
申请人: PFIZER INC.
发明人: Michael Aaron Brodney , Jennifer Elizabeth Davoren , Amy Beth Dounay , Ivan Viktorovich Efremov , David Lawrence Firman Gray , Michael Eric Green , Jaclyn Louise Henderson , Chewah Lee , Scot Richard Mente , Steven Victor O'Neil , Bruce Nelsen Rogers , Lei Zhang
IPC分类号: C07D401/12 , C07D401/14 , C07D403/12 , A61K31/501 , C07D405/14 , A61K31/444 , A61K31/506 , A61K31/513
CPC分类号: C07D401/14 , A61K31/444 , A61K31/501 , A61K31/506 , A61K31/513 , C07D401/12 , C07D403/12 , C07D405/14
摘要: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.
-
公开(公告)号:US09527831B2
公开(公告)日:2016-12-27
申请号:US14311963
申请日:2014-06-23
申请人: PFIZER INC.
发明人: Michael Aaron Brodney , Jennifer Elizabeth Davoren , Amy Beth Dounay , Ivan Viktorovich Efremov , David Lawrence Firman Gray , Michael Eric Green , Jaclyn Louise Henderson , Chewah Lee , Scot Richard Mente , Steven Victor O'Neil , Bruce Nelsen Rogers , Lei Zhang
IPC分类号: C07D401/12 , C07D401/14 , C07D405/14 , A61K31/444 , A61K31/506 , A61K31/501 , A61K31/513
CPC分类号: C07D401/14 , A61K31/444 , A61K31/501 , A61K31/506 , A61K31/513 , C07D401/12 , C07D403/12 , C07D405/14
摘要: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.
摘要翻译: 及其药学上可接受的盐; 制备过程; 中间体用于制备; 和含有这些化合物或盐的组合物及其用于治疗D1介导的(或D1相关)疾病的用途,包括例如精神分裂症(例如,其认知和负面症状),认知障碍(例如,与精神分裂症相关的认知障碍,AD ,PD或药物治疗),ADHD,冲动性,强迫性赌博,暴饮暴食,孤独症谱系障碍,MCl,年龄相关认知衰退,痴呆,RLS,帕金森病,亨廷顿舞蹈症,焦虑症,抑郁症,MDD,TRD,双相情感障碍, 慢性冷漠,慢性疲劳,创伤后应激障碍,季节性情绪障碍,社会焦虑症,产后抑郁症,血清素综合征,药物滥用和毒品依赖,药物滥用复发,Tourette综合征,迟发性运动障碍,嗜睡,白天过度 嗜睡,恶病质,注意力不集中,性功能障碍,偏头痛,SLE,高血糖症,动脉粥样硬化,血脂异常,肥胖,糖尿病,败血症,缺血后小管 坏死,肾衰竭,低钠血症,抗性水肿,发作性睡病,高血压,充血性心力衰竭,术后眼睛低血压,睡眠障碍和疼痛。
-
公开(公告)号:US09107923B2
公开(公告)日:2015-08-18
申请号:US14638677
申请日:2015-03-04
申请人: PFIZER INC.
发明人: Michael Aaron Brodney , Jennifer Elizabeth Davoren , Amy Beth Dounay , Ivan Viktorovich Efremov , David Lawrence Firman Gray , Michael Eric Green , Jaclyn Louise Henderson , Chewah Lee , Scot Richard Mente , Steven Victor O'Neil , Bruce Nelsen Rogers , Lei Zhang
IPC分类号: C07D401/12 , C07D403/12 , A61K31/506 , A61K31/444 , A61K31/513 , A61K31/501
CPC分类号: C07D401/14 , A61K31/444 , A61K31/501 , A61K31/506 , A61K31/513 , C07D401/12 , C07D403/12 , C07D405/14
摘要: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.
摘要翻译: 本发明部分提供式I化合物及其药学上可接受的盐; 制备过程; 中间体用于制备; 和含有这些化合物或盐的组合物及其用于治疗D1介导的(或D1相关)疾病的用途,包括例如精神分裂症(例如,其认知和负面症状),认知障碍(例如,与精神分裂症相关的认知障碍,AD ,PD或药物治疗),年龄相关的认知衰退,痴呆和帕金森病。
-
公开(公告)号:US20200283407A1
公开(公告)日:2020-09-10
申请号:US16880632
申请日:2020-05-21
申请人: Pfizer Inc.
发明人: Michael Aaron Brodney , Jennifer Elizabeth Davoren , Amy Beth Dounay , Ivan Viktorovich Efremov , David Lawrence Firman Gray , Michael Eric Green , Jaclyn Louise Henderson , Chewah Lee , Scot Richard Mente , Steven Victor O'Neil , Bruce Nelsen Rogers , Lei Zhang
IPC分类号: C07D401/14 , C07D401/12 , C07D405/14 , A61P25/28 , A61P25/18 , A61K31/444 , A61K31/506 , A61K31/501 , A61K31/513 , C07D403/12
摘要: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), Parkinson's disease and chronic apathy.
-
公开(公告)号:US10696658B2
公开(公告)日:2020-06-30
申请号:US16539865
申请日:2019-08-13
申请人: Pfizer Inc.
发明人: Michael Aaron Brodney , Jennifer Elizabeth Davoren , Amy Beth Dounay , Ivan Viktorovich Efremov , David Lawrence Firman Gray , Michael Eric Green , Jaclyn Louise Henderson , Chewah Lee , Scot Richard Mente , Steven Victor O'Neil , Bruce Nelsen Rogers , Lei Zhang
IPC分类号: C07D403/12 , C07D403/14 , C07D401/12 , C07D401/14 , A61K31/501 , A61K31/444 , A61K31/506 , A61P25/18 , A61P25/28 , C07D405/14 , A61K31/513
摘要: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.
-
公开(公告)号:US09139561B2
公开(公告)日:2015-09-22
申请号:US14638608
申请日:2015-03-04
申请人: PFIZER INC.
发明人: Michael Aaron Brodney , Jennifer Elizabeth Davoren , Amy Beth Dounay , Ivan Viktorovich Efremov , David Lawrence Firman Gray , Michael Eric Green , Jaclyn Louise Henderson , Chewah Lee , Scot Richard Mente , Steven Victor O'Neil , Bruce Nelsen Rogers , Lei Zhang
IPC分类号: C07D401/12 , C07D403/12 , A61K31/506 , A61K31/444 , A61P25/18
CPC分类号: C07D401/14 , A61K31/444 , A61K31/501 , A61K31/506 , A61K31/513 , C07D401/12 , C07D403/12 , C07D405/14
摘要: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.
-
公开(公告)号:US11964961B2
公开(公告)日:2024-04-23
申请号:US17204095
申请日:2021-03-17
申请人: Pfizer Inc.
发明人: Michael Aaron Brodney , Jennifer Elizabeth Davoren , Amy Beth Dounay , Ivan Viktorovich Efremov , David Lawrence Firman Gray , Michael Eric Green , Jaclyn Louise Henderson , Chewah Lee , Scot Richard Mente , Steven Victor O'Neil , Bruce Nelsen Rogers , Lei Zhang
IPC分类号: C07D401/12 , A61K31/444 , A61K31/501 , A61K31/506 , A61K31/513 , A61P25/00 , A61P25/18 , A61P25/28 , C07D401/14 , C07D403/12 , C07D405/14
CPC分类号: C07D401/14 , A61K31/444 , A61K31/501 , A61K31/506 , A61K31/513 , A61P25/18 , A61P25/28 , C07D401/12 , C07D403/12 , C07D405/14
摘要: The present invention provides, in part, compounds of Formula I:
and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, SLE, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.-
公开(公告)号:US10093655B2
公开(公告)日:2018-10-09
申请号:US15729111
申请日:2017-10-10
申请人: PFIZER INC.
发明人: Michael Aaron Brodney , Jennifer Elizabeth Davoren , Amy Beth Dounay , Ivan Viktorovich Efremov , David Lawrence Firman Gray , Michael Eric Green , Jaclyn Louise Henderson , Chewah Lee , Scot Richard Mente , Steven Victor O'Neil , Bruce Nelsen Rogers , Lei Zhang
IPC分类号: C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , A61K31/444 , A61K31/506 , A61K31/513 , A61P25/18 , A61P25/28 , A61K31/501
摘要: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.
-
公开(公告)号:US10077272B2
公开(公告)日:2018-09-18
申请号:US15822493
申请日:2017-11-27
申请人: PFIZER INC.
发明人: David Lawrence Firman Gray , Lei Zhang , Jennifer Elizabeth Davoren , Amy Beth Dounay , Ivan Viktorovich Efremov , Chewah Lee , Scot Richard Mente , Steven Victor O'Neil , Bruce Nelsen Rogers , Chakrapani Subramanyam
IPC分类号: C07D471/04 , C07D491/048 , C07D498/04
CPC分类号: C07D491/048 , C07D471/04 , C07D498/04
摘要: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
-
-
-
-
-
-
-
-
-